Heart failure: statins for all?

Leite-Moreira, A. F.; Castro-Chaves, P.
November 2006
Heart;Nov2006, Vol. 92 Issue 11, p1537
Academic Journal
The article focuses on the debate on whether statins should be recommended to treat all heart failure patients. Studies support the benefits of using the drug in some heart failure patients. However, its benefits in patients with normocholesterolaemic non-ischemic chronic heart failure remains to be established.There is also insufficient safety data to support its use in patients, where there are potential concerns about coenzyme Q10 depletion and excessive low density lipoprotein reduction.


Related Articles

  • CHOLESTEROL & STATIN DRUGS. Davis, William // Life Extension;Nov2004, Vol. 10 Issue 11, p42 

    Focuses on the use of statin drugs in lowering blood cholesterol. Efficacy of the treatment; Citations of the possible adverse effects of constant use; Importance of using statin as a solution only after other natural alternatives have been exhausted. INSET: HOW TO SAFELY TRANSITION FROM...

  • Statins found beneficial in wider range of patients, major study finds.  // Formulary;Jan2002, Vol. 37 Issue 1, p47 

    Examines the indications for statin therapy for the trial of cholesterol- lowering therapy in Anaheim, California. Benefits of statin therapy; Reduction of vascular events in simvastatin recipients; Levels of low-density lipoprotein.

  • New Statin Trial Results Promising. Palmer, Paul R. // Access;May/Jun2001, Vol. 15 Issue 5, p16 

    Focuses on the potential of the cholesterol-reducing drug rosuvastatin to reduce low-density lipoprotein cholesterol (LDC-C). Comparison of performance with other cholesterol-reducing drugs; Percentage of LDC-C reduction by rosuvastatin; Increase in high-density lipoprotein cholesterol;...

  • Efficacy and tolerability of adding coenzyme A 400 U/d capsule to stable statin therapy for the treatment of patients with mixed dyslipidemia: an 8-week, multicenter, double-Blind, randomized, placebo-controlled study. Jiangtao Lai; Bifeng Wu; Tianming Xuan; Zhong Liu; Junzhu Chen // Lipids in Health & Disease;2014, Vol. 13 Issue 1, p1 

    Background Patients with mixed hyperlipidemia usually are in need of combination therapy to achieve low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) target values for reduction of cardiovascular risk. This study investigated the efficacy and safety of adding a new hypolipidemic...

  • Statins and Menopause. Moghadasian, M.H. // Drugs;2002, Vol. 62 Issue 17, p2421 

    During the reproductive period, women generally have lower low-density lipoprotein (LDL) cholesterol and higher high-density lipoprotein cholesterol than age- and diet-matched men. However, these possibly antiatherogenic characteristics of lipoproteins are changed to a potentially atherogenic...

  • Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Berthold, Heiner K.; Naini, Ali; Di Mauro, Salvatore; Hallikainen, Maarit; Gylling, Helena; Krone, Wilhelm; Gouni-Berthold, Ioanna // Drug Safety;2006, Vol. 29 Issue 8, p703 

    BACKGROUND: HMG-CoA reductase inhibitors (‘statins’) have been associated with a decrease in ubidecarenone (ubiquinone) levels, a lipophilic enzyme also known as coenzyme Q10 (CoQ10), due to inhibition of mevalonate synthesis. There is speculation that a decrease...

  • Fiber enhances statins.  // Cortlandt Forum;7/25/2005, Vol. 18 Issue 7, p21 

    Focuses on the effectiveness of the combination of statins and psyllium agents to lower low density lipoproteins (LDL); Decreased level of LDL in the statin and in both psyllium/statin group; Similarity of the beneficial effect of psyllium in switching to simvastatin.

  • Do elevated lipids call for more than statins? Guthrie, Robert M. // Cortlandt Forum;Jan2008, Vol. 21 Issue 1, p26 

    The article focuses on the concept of clinicians to consider adding another cholesterol-reducing agent to statins to lower the low density lipoproteins (LDL) of patients with acute coronary syndrome and to prevent cardiovascular events. But researchers have stressed that the benefits of such...

  • Novel Dietary Supplement Shows Dramatic Effects in Lowering Cholesterol, LDL, and Triglycerides. English, Jim // Life Extension;Nov2004, Vol. 10 Issue 11, p28 

    Reports on the use of Sytrinol, a dietary supplement, in lowering low density lipoproteins, triglycerides and apolipoprotein B. Components of Sytrinol; Safety profile in terms of general adverse events; Efficacy.


Read the Article


Sign out of this library

Other Topics